CSL share price climbs as $16 billion Vifor acquisition becomes effective

CSL shares are in the green on Tuesday…

| More on:
Medical technicians wearing white medical coats conduct a test in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares climb in early trading as the company completes its Vifor Pharma acquisition 
  • The company completed its acquisition after a lengthy delay
  • CSL will hold a dedicated market briefing on 17 October, discussing Vifor Pharma’s business model and financials

The CSL Limited (ASX: CSL) share price is edging higher following the completion of the company's latest acquisition.

In earlier trading, shares in the global biotech reached $298.49, up 0.96% on yesterday's closing price. They have since fallen back to $295.70, up 0.02%.

In contrast, the S&P/ASX 200 Index (ASX: XJO) is hovering 0.03% down at 7,018 points.

CSL adds Vifor Pharma to its books

After receiving all the required regulatory clearances last week, CSL has effectively taken over Vifor Pharma AG.

The acquisition comes after CSL announced a lengthy delay back in May due to some antitrust issues.

However, with the deal now settled, CSL currently holds more than 97% of Vifor shares. At the same time, these shares will soon be removed as management will apply to delist them post-close.

The remaining 3% os stock is expected to be cancelled in accordance with Swiss takeover rules.

With the $16 billion deal completed, CSL has access to Vifor Pharma's iron deficiency, dialysis, and nephrology & rare products divisions.

CSL's upcoming results are scheduled to be released on Wednesday 17 August. Of course, they won't include any earnings from Vifor Pharma.

However, adding a global pharmaceuticals company will undoubtedly boost CSL's financial profile in the H1 FY23 period.

CEO of Vifor Pharma Abbas Hussain commented:

…I am full of confidence that Vifor Pharma will have a successful future as part of a larger, global organization. This will allow us to accelerate growth and to successfully drive multiple product launches as we continue to help even more patients around the world live better, healthier lives.

It's worth noting that CSL will hold a dedicated market briefing on 17 October. Management will discuss Vifor Pharma's growth strategy and provide insights into its product portfolio as well as its financials.

CSL share price review

Following a broader recovery on the ASX, the CSL share price climbed 2.7% in the past month.

When looking at year-to-date, CSL shares are down 0.09%.

CSL is the third-largest company on the ASX. Its market capitalisation is $142.41 billion.

Should you invest $1,000 in Dyno Nobel right now?

Before you buy Dyno Nobel shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Dyno Nobel wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »